Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong. The company’s underlying business is thriving, with analysts projecting its market value could hit $1 trillion in the coming years.

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition costs. Learn more about LLY stock here.

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Eli Lilly and Company (LLY) said on Monday that the highest approved doses of its weight-loss drug Zepbound will soon be available on its digital health platform LillyDirect. The 12.5 mg and 15 mg doses will be available in single-dose vials and priced at $499 per month for self-paying customers,

Eli Lilly, Home Depot, SAP and NRP highlight key themes in pharma, retail, cloud growth???and energy sector challenges.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound. | With the move, all of Eli Lilly's Zepbound doses will soon be available in cheaper single-dose vials for $499 per month or less.